Cite
HARVARD Citation
Boyer, M. et al. (2013). Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer. Clinical investigation. pp. 29-35. [Online].